INTerpath-001 Phase 3: Personalized mRNA Cancer Vaccine Plus Pembrolizumab Cuts Melanoma Recurrence or Death Risk by 42%

The INTerpath-001 phase 3 results were presented at the ESMO annual meeting. A personalized mRNA cancer vaccine combined with pembrolizumab reduced the risk of recurrence or death by 42% in patients with high-risk melanoma after surgery. The study enrolled 1137 patients with completely resected stage IIB to IV disease, randomized 2:1. At a median follow-up of 24.6 months, recurrence-free survival showed an HR of 0.58, p<0.001; two-year recurrence-free survival rates were 82.2% versus 70.0%, with benefit separating after 6 months.